Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice

Oncology (Switzerland)

Volumn 84, Issue 5, 2013, Pages 255-264

  Zugazagoitia, J ^a   Puente, J ^a   Gonzalez Larriba J L ^a   Manzano, A ^a   Sotelo, M ^a   Hernandez S ^a   Sanz, J ^a   Perez P ^a   Diaz Rubio E ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Erlotinib; Non small cell lung cancer; Non squamous tumors; Pemetrexed; Second line therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HAIR LOSS; HISTOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARONYCHIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SMOKING; THROMBOCYTOPENIA;

EID: 84874009536     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000346534     Document Type: Article

References (30)

1. American Cancer Society: Cancer Facts & Figures, 2009. Atlanta, American Cancer Society, Inc., 2009.
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
4. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
5. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
6. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
7. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
8. De Maio E, Tibaldi C, D'Incecco A, et al: Consequences of targeted treatments for secondline therapy. Ann Oncol 2010; 21(suppl 7): vii234-vii240.
9. Sheperd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353: 123-132.
10. Hanna N, Sheperd FA, Fosella F, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
11. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: a review or two phase III studies. Oncologist 2009; 14: 253-263.
12. Ciuleanu T, Stelmakh L, Cicenas S, et al: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; 13: 300-308.
13. Vamvakas L, Agelaki S, Kentepozidis NK, et al: Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small-cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology research group trial. Proc Am Soc Clin Oncol 2010; 28(suppl): 7519.
14. Kargi A, Gurel D, Tuna B: The diagnostic value of TTF-1, CK 5/6 and p 63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415-420.
15. Pan Q, Pao W, Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005; 7: 396-403.
16. Cedres S, Prat A, Martinez P, et al: Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009; 66: 257-261.
17. Leton E, Zuluaga P: Relationships among tests for censored data. Biom J 2005; 47: 377-387.
18. Di Maio M, Chiodini P, Georgoulias V, et al: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced nonsmall-cell lung cancer. J Clin Oncol 2009; 27: 1836-1843.
19. Paz-Ares L: Beyond first-line NSCLC therapy: chemotherapy or erlotinib? Lancet Oncol 2012; 13: 225-227.
20. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
21. Kim ES, Hirsh V, Mok TS, et al: Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-1818.
22. Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated nonsmall cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2009; 28: 744-752.
23. Heigener DF, Wu YL, van Zandwijk N, et al: Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer 2011; 74: 274-279.
24. Garassino MC, Martelli O, Bettini A, et al: TAILOR: a phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 2012; 30: LBA7501.
25. Mitchell P, Mok T, Barraclough H, Strizek A, Lew R, van Kooten M: Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. Clin Lung Cancer 2012; 13: 239-251.
26. Clark GM, Zborowski DM, Santabarbara P, et al: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7: 389-394.
27. Hamilton M, Wolf JL, Zborowski D, et al: Tarceva TM (erlotinib) exposure/effects (EE) analysis from a phase III study in advanced NSCLC: effect of smoking on the PK of erlotinib. Proc Am Assoc Cancer Res 2005; 46: 56.
28. Hamilton M, Wolf JL, Rusk J, et al: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166-2171.
29. Hoffmann-La Roche: A Study of Tarceva (Erlotinib) to Compare Two Different Doses in Currently Smoking Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS). http://clinicaltrials.gov/ct2/show/NCT01183858 NLM Identifier NCT01183858.
30. Mitsudomi T, Kosaka T, Yatabe Y: Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006; 11: 190-198.